Assessing Pharmaceutical Research and Development Costs: To the editor

T. van der Gronde, A.H.L.M. Pieters

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Abstract

In their Original Investigation published in a recent issue of JAMAInternal Medicine, Prasad and Mailankody examine the costs of bringing a single drug with an oncological indication to the market. They conclude that 10 selected companies had a median investment cost of $648 million for the development of their drug, whereas the median revenue in 4 years on average was $1658.4 million. This further reinforces the notion that there are large profits to be made with drug development, and that current pharmaceutical drug prices are unrelated to the actual costs for research and development.
Original languageEnglish
Pages (from-to)587-588
Number of pages2
JournalJAMA Internal Medicine
Volume178
Issue number4
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • antineoplastic agent
  • drug cost
  • drug indication
  • drug industry
  • human
  • investment
  • letter
  • outcome assessment
  • priority journal

Fingerprint

Dive into the research topics of 'Assessing Pharmaceutical Research and Development Costs: To the editor'. Together they form a unique fingerprint.

Cite this